Answers are grounded in this paper and cite their sources.
Background and Aims: Ketamine is being proposed for the prevention of rebound pain. This meta-analysis systematically reviews evidence from randomised controlled trials on the efficacy of ketamine (intravenous or perineural) in preventing rebound pain in adults undergoing surgery under regional nerve block. Methods: A systematic search for randomised controlled trials evaluating ketamine/esketamine (perineural or intravenous) for preventing rebound pain was conducted across databases up to March 2025. Adults receiving regional nerve block with or without ketamine/esketamine were included. The primary outcome was the incidence of rebound pain. Secondary outcomes included onset time and severity of rebound pain, patient satisfaction, and adverse effects. Results: Six trials enroling 890 patients were included. Ketamine/esketamine significantly reduced the incidence of rebound pain [odds ratio (OR) 0.43, 95% confidence interval (CI) 0.32 to 0.59; P < 0.00001; I ² = 39%]. The intravenous subgroup showed a significant reduction (OR 0.48, 95% CI 0.34 to 0.68; P < 0.00001; I ² = 21%). The esketamine-versus-control subgroup also favoured active treatment (OR 0.37, 95% CI 0.22 to 0.64; P = 0.0004; I ² = 51%). Hallucinations were significantly more frequent with active treatment (OR 12.73, 95% CI 2.98 to 54.41; P = 0.0006; I ² = 0%). Conclusion: Current evidence suggests that intravenous and perineural ketamine/esketamine reduce the incidence of rebound pain after a peripheral regional nerve block.
No takes yet. Share an insight, caveat, or question.
Makkar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: